Full Press Release Details
Disclaimer This presentation (together with oral statements made in
connection herewith, this "Presentation") is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in
any states or jurisdictions in which such offer, solicitation or sale would be unlawful. Forward Looking Statements Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the
safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward- looking statements generally are accompanied by words such as "believe," "may," "will,"
"estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem,"
"seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited
to, statements by NewAmsterdam Pharma Company N.V. ("NewAmsterdam" or the "Company") regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity; expectations and timing
related to the success, cost and timing of product development activities, including timing of initiation, completion and data readouts for clinical trials and the potential approval of the Company's product candidate; the timing for enrolling
patients; the timing and forums for announcing data; the size and growth potential of the markets for the Company's product candidate; the therapeutic and curative potential of the Company's product candidate; financing and other
business milestones; the Company's expected cash runway; and the Company's plans for commercialization. These statements are based on various assumptions, whether or not identified in this Presentation, and on the current expectations of
the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a
prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These
forward- looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of NewAmsterdam's product
candidate and the timing of expected regulatory and business milestones; whether topline, initial or preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical
trials will be indicative of the results of later clinical trials; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials;
global economic and political conditions, including the Russia-Ukraine conflict, and the war in Israel; the effects of competition on NewAmsterdam's future business; and those factors discussed in documents filed by the Company with the SEC.
Additional risks related to NewAmsterdam's business include, but are not limited to: uncertainty regarding outcomes of the company's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its
product candidate; risks associated with the Company's efforts to commercialize a product candidate; the Company's ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product
candidates on the Company's business; intellectual property-related claims; the Company's ability to attract and retain qualified personnel; and the Company's ability to continue to source the raw materials for its product
candidate, together with the risks described in the Company's filings made with the U.S. Securities and Exchange Commission from time to time. If any of these risks materialize or NewAmsterdam's assumptions prove incorrect, actual
results could differ materially from the results implied by these forward-looking statements. There may be additional risks that are presently unknown by the Company or that NewAmsterdam currently believes are immaterial that could also cause actual
results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect NewAmsterdam's expectations, plans, or forecasts of future events and views as of the date of this Presentation and are
quali ed in their entirety by reference to the cautionary statements herein. NewAmsterdam anticipates that subsequent events and developments will cause the Company's assessments to change. These forward-looking statements should not be
relied upon as representing NewAmsterdam's assessments as of any date subsequent to the date of this Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither NewAmsterdam nor any of its
affiliates undertakes any obligation to update these forward-looking statements, except as required by law. Market Data Certain information contained in this Presentation relates to or is based on third-party studies, publications, surveys and
NewAmsterdam's own internal estimates and research. In addition, all of the market data included in this Presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such
assumptions. Finally, while NewAmsterdam believes its internal research is reliable, such research has not been verified by any independent source and NewAmsterdam cannot guarantee and makes no representation or warranty, express or implied, as to
its accuracy and completeness. Trademarks This Presentation contains trademarks, service marks, trade names, and copyrights of NewAmsterdam and other companies, which are the property of their respective owners. The use or display of third
parties' trademarks, service marks, trade name or products in this Presentation is not intended to, and does not imply, a relationship with NewAmsterdam or an endorsement or sponsorship by or of NewAmsterdam. Solely for convenience, the
trademarks, service marks and trade names referred to in this Presentation may appear with the TM or SM symbols, but such references are not intended to indicate, in any way, that NewAmsterdam will not assert, to the fullest extent permitted under
applicable law, their rights or the right of the applicable licensor to these trademarks, service marks and trade names. 2
Obicetrapib in multiple Phase 3 trials for hypercholesterolemia -
Key value- driving data expected in 2024 Significant unmet need for oral LDL-lowering therapy as adjunct Multiple pivotal data readouts to statins: expected from 2024-2026 35mm+ patients in US/EU5 are not achieving LDL-lowering 1Q
2024: Complete Phase 3 enrollment for PREVAIL goals despite standard-of-care 1Q 2024: Initiate Phase 3 fixed-dose combination ("FDC") trial $3-4B+ global market opportunity Anticipated Phase 3 data readouts: Simple, oral,
once-daily, low dose CETP inhibitor with strong LDL-lowering observed through five Phase 2 trials: 3Q 2024: BROOKLYN 4Q 2024: BROADWAY 43% mean LDL-lowering as monotherapy, 59% mean in 1Q 2025: TANDEM Fixed-Dose
Combination combination with ezetimibe, observed on top of high- 2026: PREVAIL CVOT intensity statins Additional pipeline expansion potential in Alzheimer's Tolerability data in >800 pts, with blinded data in >10,000 pts
disease and diabetes Robust effects on ApoB, non-HDL-C, HDL-C and Lp(a) Upcoming catalysts build on 2023 progress: Convenient oral format potentially enables broad market access to address unmet need Enrollment Positive data in Initial data
from (1) complete in ROSE2, Phase 2b Cash at year end 2023: ~$340 million Phase 2a Trial in BROOKLYN & Trial in Japanese Early Alzheimer's BROADWAY Patients Source: Company data for obicetrapib 10mg monotherapy, Pooled data includes TULIP,
ROSE, ROSE2, and Japan Phase 2 data sets Note: 1. unaudited 3
Obicetrapib designed to address the ~30M patients in US on drug but not
at goal ~18 million ~43 million Not at goal of LDL-C Treated primary <100mg/dl prevention patients Of the ~30M treated patients not at goal, ~8 million ~72 million ~19 million High Risk ASCVD not at ~18M were "far from Adults in US
diagnosed with Treated secondary goal of LDL-C <55 mg/dl hypercholesterolemia goal" (greater than prevention patients 20%) and 6M were not taking statins ~5 million ASCVD not at goal of LDL-C <70 mg/dl ~10 million Diagnoses patients not
treated with statin or LLT US Branded Lipid Lowering Market Potential key factors limiting penetration include product limitations and market access hurdles: Low prescriber enthusiasm for existing TPPs Payors restrict access ASCVD=atherosclerotic
cardiovascular disease; HeFH=heterozygous familial hypercholesterolemia; LDL-C=low-density lipoprotein-cholesterol; LLT=lipid lowering treatment. 4 Source: Merative Marketscan Claims Linked with Lab Data, 2019 - 2022, 12 months continuous data for
each patient (6 months LB and 6 months LF from 1st observed statin treatment
Majority of ASCVD/HeFH patients are not achieving LDL-C targets Primary
prevention HeFH Despite availability of ASCVD patients with an LDL-C Very high risk ASCVD patients patients with treatments continue to see target of LDL<70 or <55 mg/dL with an LDL-C target <55 an LDL-C target <100 mg/dL minimal uptake,
especially 2 3 (2017-2018) mg/dL (2020-2021) 1 4 (2011-2017) adjunct to statins Statin utilization LDL-C < 100 LDL-C < 70 LDL-C < 55 65.8M mg/dL mg/dL mg/dL 29.6M 29% 24% 10% PCSK9i utilization 9.7M <1/3 achieved <1/4 achieved 10%
achieved LDL-C <100 mg/dL LDL-C <70 mg/dL LDL-C <55 mg/dL 0.253M ASCVD=atherosclerotic cardiovascular disease; HeFH=heterozygous familial hypercholesterolemia; LDL-C=low-density lipoprotein-cholesterol. 1. Schreuder MM, et al. LDL
cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis. Atherosclerosis. 2023 2. Gao Y, Shah LM, Ding J, Martin SS. US trends in cholesterol screening, lipid levels, and lipid-lowering
medication use in US adults, 1999 to 2018. J Am Heart Assoc. 2023;12(3):e028205; 3. Katzmann JL, et al. Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high 5 and very-high
cardiovascular risk. PLoS One. 2022;17(10):e0276898; 4. J Am Heart Assoc 2022;11:3026075; doi: 10.1161/JAHA.122.026075
Increased CV events following removal of LDL-C guidelines in 2013 15
Risk of CV 70 LDL-C death, MI, 55- 70 LDL-C LDL-C stroke goals Male deaths 40- 55 LDL-C removed 10 in 20 LDL-C 2013 5 Female deaths P-value = 0.0001 5 0 0 1 2 3 4 5 Trends in prevalence of high LDL-C in US adults, 2 Year
Time post-enrollment (years) NHANES 1999-2018 with history of ASCVD Numerous studies Despite statins, CVD deaths ~75% of ASCVD patients are NOT demonstrate resurgence of are on the rise at their risk-based LDL-C goal paradigm "lower is
better" Sources: Trinity NewAmsterdam Market Research Summary; Trinity quantitative market research with N = 100 PCPs and Cardiologists; Bloomberg Prescription Data; IQVIA Rx Tracker. (1) Literature review suggesting hypercholesterolemia
prevalence of ~94mm in the US (average of He et al. 2020, Mercado et al. 2015, Muntner et al. 2013) and ~137mm in EU5 (average of Gomez-Huelgas et al. 2010, Guallar-Castillon et al. 2012, Tragni et al. 2012, Grau et al. 2011 (3) 8mm
statin-intolerant & 22mm above LDL-C target: Percentage of patients in each category estimated from Trinity quantitative market research and the - percentages were then applied to the estimated 84mm treated number above. (4) <1mm
branded patients: 2020 US prescription data for Repatha, Praluent, and Nexletol/Nexlizet were pulled from the Bloomberg Prescription Data Portal that Trinity subscribes to; assuming 12 scripts/year and 70% compliance for PCSK9s (based on PCSK9
literature) and 59% compliance for Nex/Nex (based on statin literature) patient volume estimates were derived from the prescription data and extrapolated to the EU5. (5) Gaba P, et. al., Association Between Achieved Low-Density Lipoprotein
Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023 Feb 13. doi: 10.1161/CIRCULATIONAHA.122.063399. 6 Deaths in Thousands Cumulative incidence rate (%)
Resurgence of the "lower is better" paradigm leading to
significant US market growth 18% 3yr CAGR LDL-C goals removed Mortality 7% peaks 3yr CAGR Driven by generic ezetimibe, 7% total market growth in 18% non-statin patient growth given lack of convenient and the US efficacious alternatives Recent
guideline and label changes driving renewed acceleration June 2023: ACC updated guidelines to target LDL-C <55 mg/dl in high risk patients in line with ESC/EAS November 2023: FDA highlights need to reduce access restrictions for LLTs. Labels
updated from "on top of maximally tolerated statins" to "treatment of primary hyperlipidemia" for some LLTs 7 Source: Symphony Health data through October 2023 Note: LLT=lipid lowering treatment.
Few approved post-statin LDL lowering products, which are limited by
efficacy, convenience and/or payor access (5) (5) (4) (1) (2) (3) Obicetrapib Obi + Eze Oral PCSK9 Ezetimibe Nexletol PCSK9i LDL data 2026E LDL data 2024E Approved Approved Approved LDL data 2025E Approval (CVOT data 2029E) (CVOT data 2026E) MACE
Benefit 7% 13% 15% TBD TBD TBD Observed LDL-C 25% 15% 45-50% 43-51% 63% 50-59% Reduction Oral Oral Injectable Oral Oral Oral Administration (small molecule) (small molecule) (mAb) (peptide) (small molecule) (small molecule) 380mg 20mg 10mg 180mg
140-150mg 10mg Dosing (20mg API + 360mg SNAC) (10mg Obi + 10mg Eze) Yes No No No No No Food Effect (8hr fast & 30min wait) SNAC technology Safety & Safe, Tendon rupture & gout Safe, has previously been Well-Tolerated Well-Tolerated
Well-Tolerated warning on label injection site reactions observed to have compared to placebo compared to placebo Tolerability (6) tolerability concerns Raises None 15-30% 20-25% 47-57% 40% Lp(a) lowering Note: The above data do not represent
head-to-head comparisons. Actual results may differ from expectations. Obicetrapib mono and Ezetimibe combo, along with the Oral PCSK9 have not been approved by any regulatory authority. E= estimated dates. Sources: 1. PI Zetia table 7. refers to;
Gagne, C et al. Am J Cardiol 2002. LDL-C measured only using Friedewald 2. PI Nexletol; study 2. refers to; Goldberg, A et al. JAMA 2019;322(18):1780-1788. LDL-C measured using Friedewald and direct assay for LDL-C <50 mg/dL. 3. 8 multiple
studies: Blom, D et al. N Engl J Med 2014; Kereiakes, D et al. Am Heart J 2015.; Ray, K. N Engl J Med 2020. 4. Ballantyne, C et al. JACC 2023;81(16) 5. See slide 11 and 17 6. MK0616 was observed to have adverse events comparable to pbo in Phase 2b
40-50% LDL-C reduction comparable to high efficacy PCSK9 injectables
Cross trial comparison of LDL-C reduction across different approaches (in %) Anacetrapib Evacetrapib Dalcetrapib Ezetimibe Nexletol Repatha Praluent Leqvio 1 2 3 4 5 6 7 8 100mg 130mg 600mg 10mg 180mg 420mg 150mg 284mg 0 Prior CETP inhibitors
Existing oral therapies PCSK9 injectables -7 -10 -15 -17 Nexletol bears -21 FDA label for tendon -20 rupture, gout -25 Ezetimibe is generic -30 -40 -46 -47 -51 -50 -60 -70 The trials represented were selected due to their shared features that
reflect the Phase 3 obicetrapib studies. Selecting trials with shared features allows for a potentially more accurate comparison of the LDL-C lowering results, with factors being considered such as: a) presence of intensive LDL-lowering therapy
including (high intensity) statins and PCSK9 inhibitors, b) patient population - ASCVD or ASCVD risk equivalent patients (including primary hypercholesterolemia and HefH) and c) where possible, selected studies where LDL-C measured by
preparative ultracentrifugation (PUC ) as opposed to Friedewald; noted below are those instances where PUC was not used - this is important because at low LDL-C levels (< 50 mg/dL), calculated LDL-C by Friedewald is overestimated; certain
significant deviations from these parameters are provided in the footnotes. Note: The above trials and data do not represent head-to-head comparisons. Actual results may differ from expectations. Sources: * Circulation. 2021;144:e564-e593
17065. 1. Bowman, L et al. N Engl J Med 2017. 2. Amirhossein, S et al. Curr Pharmaceutical Design 2016. Meta-analysis - Also included hyperlipidaemia patients. LDL-C measured using direct assays and Friedewald. 3. de Grooth et al. Circulation 2002.
LDL-C measured only using Friedewald and did not require subjects to be on prior statin therapy or present with ASCVD. 4. PI Zetia table 7. refers to; Gagne, C et al. Am J Cardiol 2002. LDL-C measured only using Friedewald. 5. PI Nexletol; study 2.
refers to; Goldberg, A et al. JAMA 2019;322(18):1780-1788. LDL-C measured using Friedewald and direct assay for LDL-C <50 mg/dL. 6. DESCARTES study. refers to; Blom, D et al. N Engl J Med 2014. Also 9 included hyperlipidaemia patients. 7. PI
Praluent; study 3. refers to; Kereiakes, D et al. Am Heart J 2015. 8. PI Leqvio; study 1. Refers to; Ray, K. N Engl J Med 2020. % LDL-C change versus baseline
Obicetrapib program designed to overcome limitations of prior CETP
inhibitors (3) (1) (2) (4) (5) Evacetrapib Torcetrapib Dalcetrapib Anacetrapib Obicetrapib Observed LDL-C reduction 20% 7% 21% 17% 43% CETP inhibition 80% 40% 65% 90% 98% Dosing 60mg 600mg 100mg 100mg 10mg Blood pressure increase Yes No No No No
Aldosterone increase Yes No No No No Lp(a) lowering unknown unknown 20-25% 20-25% 47-57% ApoB lowering 10% None 15% 18% 25%-35% OUTCOMES STUDIES Name ILLUMINATE Dal-OUTCOMES ACCELERATE REVEAL PREVAIL Patients 15,067 15,871 12,092 30,449 >9,000
(expected) Baseline LDL-C (mg/dl) 79.7 76.4 81.1 61 ~105 (expected) LDL-C reduction (mg/dl) 20 NS 25 11 TBD Median follow-up 18 mo 31 mo 26 mo 49 mo 42 mo (expected) Result (HR) 1.25 1.04 1.01 0.91 TBD Short follow-up but As expected, low
Explanation Off target tox No LDL-C benefit mortality benefit (HR baseline and LDL TBD 0.84) reduction Note: The above trials and data do not represent head-to-head comparisons. Actual results may differ from expectations. 10 Sources: 1. Barter et
al. NEJM.2007; 2. Schwartz et al. NEJM.2012; 3. Lincoff et al. NEJM.2017 4. Bowman et al. NEJM.2017 5. Company Data
Enhanced LDL-C reduction with Obicetrapib's greater potency Note:
The above trials and data do not represent head-to-head comparisons. Actual results may differ from expectations. 11 Sources: 1. Barter et al. NEJM.2007; 2. Schwartz et al. NEJM.2012; 3. Lincoff et al. NEJM.2017 4. Bowman et al. NEJM.2017 5. Company
Obicetrapib Phase 1/2 studies: Consistent benefits observed in lipid
biomarkers Phase 1 MAD ROSE ROSE2 Japan Pooled data TA-8995-06 TULIP N=10 per arm N=40 per arm N=26 per arm N=26 per arm N=132 N=13 per arm N=35 per arm Median LS Mean Source: Company data for obicetrapib 10mg monotherapy, Pooled data includes
TULIP, ROSE, ROSE2, and Japan Phase 2 data sets 12
Sufficient cash expected to fund the Company through multiple potential
pivotal data readouts 2024-2026 2024 2022 2023 2024 2025 2026 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H Phase 3 BROADWAY Trial Lipid Mono Study BROADWAY Ph3 (HeFH or ASCVD; LDL-C 55 mg/dL; LDL n=2,532) regulatory filing BROOKLYN Ph3 Phase 3 BROOKLYN
Trial Lipid Mono Study (HeFH; LDL-C 70 mg/dL; HeFH; n=354) Obicetrapib MACE Monotherapy PREVAIL CVOT regulatory Phase 3 CVOT PREVAIL Trial Product filing (ASCVD or HeFH; LDL-C 70 mg/dL; (obicetrapib 10mg) n=9,000) Japan Ph2b Phase 2b
Japan Trial (LDL-C 70 mg/dL; n=100) LEGEND Ezetimibe FDC Phase 2b ROSE2 Trial Initiation ROSE2 Ph2b (LDL-C 70 mg/dL; n=114) LDL Product Enrollment regulatory (obicetrapib 10mg + complete filing ezetimibe 10mg) FDC Ph3 Phase 3 FDC
Trial Ph3 readout (LDL-C 70 mg/dL; n=400) CVOT readout Alzheimer's Ph2 readout Product Phase 2a Alzheimer's Alzheimer's Ph2a (proprietary Disease Trial dose/formulation (ApoE4 carrier; n=10-15) incorporating